Author

D. D. Ho

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 31 Immunology· 13 Biochemistry· 2 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 45 Research Focus:host-pathogen & immune response· 37 Organism:human· 24 Organism:virus· 15 Assay:proteomics· 13 Research Focus:drug response / drug discovery· 8 Assay:structural biology· 8 Organism:mouse· 3

Frequent Co-Authors

L. Liu· 30 shared Y. Guo· 24 shared Y. Huang· 23 shared J. Yu· 21 shared Q. Wang· 18 shared Z. Sheng· 17 shared P. Wang· 16 shared M. S. Nair· 15 shared

Activity by Year

2020-2024 · peak 12/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

30 shared papersMicrobiology

L. Liu

Mutual co-authors in cluster

Author profile →

47 papers

Recent·Most cited

Global variation in prior exposure shapes antibody neutralization profiles of SARS-CoV-2 variants up to BA.2.86

S. Turner, G. Amirthalingam, D. Bailey, D. H. Barouch, K. R. Bewley, K. Brown, Y. R. Cao, Y.-W. Chan, S. Charlton, DOVE consortium, N. S. Coombes, B. Hallis, D. D. Ho, F. Jian, N. Lasrado, , D. J. Smith

The paper analyzes antibody neutralization data from multiple countries to assess how prior exposure to SARS-CoV-2 variants affects neutralization profiles of BA.2.86 and its descendants.

bioRxiv · Mar 27, 2024 · PreprintImmunology

SARS-CoV-2 Omicron BA.2.87.1 Exhibits Higher Susceptibility to Serum Neutralization Than EG.5.1 and JN.1

Q. Wang, Y. Guo, L. T. Schwanz, I. A. Mellis, Y. Sun, Y. Qu, G. Urtecho, R. Valdez, E. Stoneman, A. Gordon, H. H. Wang, L. Liu, D. D. Ho

This study compares the antibody evasion, ACE2 binding, and infectivity of SARS-CoV-2 BA.2.87.1 with EG.5.1 and JN.1, finding BA.2.87.1 has lower immune evasion and reduced infectivity.

bioRxiv · Mar 10, 2024Microbiology

Robust SARS-CoV-2 Neutralizing Antibodies Sustained through Three Months Post XBB.1.5 mRNA Vaccine Booster

Q. Wang, I. A. Mellis, Y. Guo, C. Gherasim, R. Valdez, A. Gordon, L. Liu, D. D. Ho

This study shows that neutralizing antibodies against SARS-CoV-2 variants remain stable for three months after an XBB.1.5 mRNA vaccine booster.

bioRxiv · Feb 16, 2024 · PreprintImmunology

Persistence of an infectious form of SARS-CoV-2 post protease inhibitor treatment of permissive cells in vitro

M. S. Nair, M. I. Luck, Y. Huang, Y. Sabo, D. D. Ho

The paper shows that an infectious intermediate form of SARS-CoV-2 persists in vitro after protease inhibitor treatment, potentially explaining viral rebound in patients.

bioRxiv · Dec 20, 2023 · PreprintMicrobiology

XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against emerging SARS-CoV-2 variants

Q. Wang, Y. Guo, A. Bowen, I. A. Mellis, R. Valdez, C. Gherasim, A. Gordon, L. Liu, D. D. Ho

XBB.1.5 monovalent mRNA vaccine booster significantly increases neutralizing antibodies against multiple SARS-CoV-2 variants in both uninfected and previously infected individuals.

bioRxiv · Nov 26, 2023 · PreprintImmunology

Antigenicity and receptor affinity of SARS-CoV-2 BA.2.86 spike

Q. Wang, Y. Guo, L. Liu, L. T. Schwanz, Z. Li, J. Ho, R. M. Zhang, S. Iketani, J. Yu, Y. Huang, Y. Qu, R. Valdez, A. S. Lauring, A. Gordon, H. H. Wang, , D. D. Ho

This paper evaluates the antigenicity and receptor affinity of the SARS-CoV-2 BA.2.86 subvariant, finding it not more resistant to human sera than other variants but with specific mAb resistance and high receptor affinity.

bioRxiv · Sep 24, 2023Microbiology

Antibody Neutralization of Emerging SARS-CoV-2: EG.5.1 and XBC.1.6

Q. Wang, Y. Guo, R. M. Zhang, J. Ho, H. Mohri, R. Valdez, D. M. Manthei, A. Gordon, L. Liu, D. D. Ho

This study evaluates antibody neutralization resistance of SARS-CoV-2 variants EG.5.1 and XBC.1.6 using pseudovirus assays and sera/mAbs, finding distinct evasion profiles and suggesting immunological imprinting and non-evasion-driven prevalence.

bioRxiv · Aug 21, 2023 · PreprintMicrobiology

SARS-CoV-2 Neutralizing Antibodies Following a Second BA.5 Bivalent Booster

Q. Wang, A. Bowen, J. Ho, R. Zhang, R. Valdez, E. Stoneman, A. Gordon, L. Lihong, D. D. Ho

This study evaluates the effect of a second BA.5 bivalent booster on SARS-CoV-2 neutralizing antibodies in elderly individuals, finding no significant increase in Omicron-specific titers after the second dose.

bioRxiv · Aug 13, 2023 · PreprintMicrobiology

Deep immunological imprinting due to the ancestral spike in the current bivalent COVID-19 vaccine

Q. Wang, Y. Guo, A. R. Tam, R. Valdez, A. Gordon, L. Lihong, D. D. Ho

This study shows that the ancestral spike in bivalent COVID-19 vaccines causes deep immunological imprinting, limiting antibody breadth against Omicron subvariants.

bioRxiv · May 3, 2023Microbiology

Antibodies that neutralize all current SARS-CoV-2 variants of concern by conformational locking

L. Liu, R. G. Casner, Y. Guo, Q. Wang, S. Iketani, J. F.-W. Chan, J. Yu, B. Dadonaite, M. S. Nair, H. Mohri, E. R. Reddem, S. Yuan, V. K.-M. Poon, C. C.-S. Chan, K.-Y. Yuen, , D. D. Ho

This study identifies two antibodies that neutralize all SARS-CoV-2 variants by locking the spike protein in a down conformation, showing a novel mechanism and potential for prophylaxis.

bioRxiv · Apr 8, 2023 · PreprintMicrobiology

Evolving antibody evasion and receptor affinity of the Omicron BA.2.75 sublineage of SARS-CoV-2

Q. Wang, Z. Li, Y. Guo, I. A. Mellis, S. Iketani, M. Liu, J. Yu, R. Valdez, A. S. Lauring, Z. Sheng, A. Gordon, L. Liu, D. D. Ho

The paper analyzes the receptor affinity and antibody evasion properties of SARS-CoV-2 BA.2.75 subvariants, identifying two evolutionary pathways and three mutations that influence their virological features.

bioRxiv · Mar 22, 2023Microbiology

Impaired potency of neutralizing antibodies against cell-cell fusion mediated by SARS-CoV-2

Q. Wang, A. Y. Yeh, Y. Guo, H. Mohri, J. Yu, D. D. Ho, L. Liu

This study develops a high-throughput assay to quantify SARS-CoV-2 spike-mediated cell-cell fusion and finds that it is more resistant to antibody inhibition than cell-free infection.

bioRxiv · Mar 9, 2023Microbiology

SARS-CoV-2 Neutralizing Antibodies After Bivalent vs. Monovalent Booster

Q. Wang, A. D. Bowen, A. R. Tam, R. Valdez, E. Stoneman, I. A. Mellis, A. Gordon, L. Liu, D. D. Ho

This study compares neutralizing antibody titers after bivalent and monovalent mRNA boosters and BA.5 breakthrough infection, finding no significant difference at one month but higher titers in breakthrough patients at three months.

bioRxiv · Feb 13, 2023 · PreprintMicrobiology

Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants

Q. Wang, S. Iketani, Z. Li, L. Liu, Y. Guo, Y. Huang, A. D. Bowen, M. Liu, M. Wang, J. Yu, R. Valdez, A. S. Lauring, Z. Sheng, H. H. Wang, A. Gordon, , D. D. Ho

This study shows that new SARS-CoV-2 BQ and XBB subvariants have significantly reduced neutralization by vaccines and monoclonal antibodies, suggesting a threat to current immunity.

bioRxiv · Nov 23, 2022Microbiology

Antibody avidity and multi-specificity combined to confer protection against SARS-CoV-2 and resilience against viral escape

C. Burn Aschner, K. Muthuraman, I. Kucharska, H. Cui, K. Prieto, M. S. Nair, M. Wang, Y. Huang, N. Christie-Holmes, B. Poon, J. Lam, A. Sultana, R. Kozak, S. Mubareka, J. L. Rubinstein, , J.-P. Julien

This study develops a multimeric antibody platform (Multabody) that enhances neutralization potency and breadth against SARS-CoV-2 and its variants through avidity and multi-specificity.

bioRxiv · Oct 23, 2022 · PreprintImmunology

Antibody responses to Omicron BA.4/BA.5 bivalent mRNA vaccine booster shot

Q. Wang, A. Bowen, R. Valdez, C. Gherasim, A. Gordon, L. Lihong, D. D. Ho

This study compares neutralizing antibody responses to bivalent and monovalent mRNA vaccines against SARS-CoV-2 variants, finding similar titers for bivalent vaccines against Omicron BA.4/BA.5 and ancestral strains.

bioRxiv · Oct 22, 2022 · PreprintMicrobiology

A pseudovirus system enables deep mutational scanning of the full SARS-CoV-2 spike

B. Dadonaite, K. H. Crawford, C. E. Radford, A. G. Farrell, T. C. Yu, W. W. Hannon, P. Zhou, R. Andrabi, D. R. Burton, L. Liu, D. D. Ho, R. A. Neher, J. D. Bloom

This paper introduces a pseudovirus system for deep mutational scanning of SARS-CoV-2 spike protein mutations, showing how they affect antibody neutralization and infection.

bioRxiv · Oct 13, 2022Microbiology

Resistance of SARS-CoV-2 Omicron Subvariant BA.4.6 to Antibody Neutralization

Q. Wang, Z. Li, J. Ho, Y. Guo, A. Y. Yeh, M. Liu, M. Wang, J. Yu, Z. Sheng, L. Liu, D. D. Ho

This study evaluates the neutralization resistance of SARS-CoV-2 Omicron subvariants BA.4.6, BA.4.7, and BA.5.9 to antibodies, finding increased resistance to certain monoclonal antibodies and vaccine-induced sera.

bioRxiv · Sep 5, 2022 · PreprintMicrobiology

Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir

S. Iketani, H. Mohri, B. Culbertson, S. J. Hong, Y. Duan, M. I. Luck, M. K. Annavajhala, Y. Guo, Z. Sheng, A.-C. Uhlemann, S. P. Goff, Y. Sabo, H. Yang, A. Chavez, D. D. Ho

This study identifies multiple mutational pathways leading to nirmatrelvir resistance in SARS-CoV-2 through in vitro experiments and structural analysis.

bioRxiv · Aug 7, 2022Microbiology

Antigenic characterization of the SARS-CoV-2 Omicron subvariant BA.2.75

Q. Wang, S. Iketani, Z. Li, Y. Guo, A. Y. Yeh, M. Liu, J. Yu, Z. Sheng, Y. Huang, L. Liu, D. D. Ho

This study characterizes the antigenic properties of the SARS-CoV-2 Omicron subvariant BA.2.75, showing increased neutralization resistance to vaccinated sera and specific monoclonal antibodies.

bioRxiv · Jul 31, 2022Microbiology

The Functional Landscape of SARS-CoV-2 3CL Protease

S. Iketani, S. J. Hong, J. Sheng, F. Bahari, B. Culbertson, F. F. Atanaki, A. K. Aditham, A. F. Kratz, M. I. Luck, R. Tian, S. P. Goff, H. Montazeri, Y. Sabo, D. D. Ho, A. Chavez

This study maps the functional landscape of SARS-CoV-2 3CL protease by profiling all single mutants and identifies resistance mutations to nirmatrelvir.

bioRxiv · Jun 23, 2022 · PreprintMicrobiology

Prefusion-Stabilized Lassa Virus Trimer Identifies Neutralizing Nanobodies and Reveals an Apex-Situated Site of Vulnerability

J. Gorman, C. S.-F. Cheung, Z. Duan, Y. Sun, P. Wang, J. C. Boyington, A. Biju, T. Bylund, C. Cheng, L. Ou, T. Stephens, Y. Tsybovsky, R. Verardi, S. Wang, Y. Yang, , P. D. Kwong

This paper develops a prefusion-stabilized Lassa virus GPC, identifies a neutralizing nanobody, and reveals a cleavage-dependent site of vulnerability at the trimer apex.

bioRxiv · Apr 21, 2022 · PreprintImmunology

Antibody Evasion Properties of SARS-CoV-2 Omicron Sublineages

S. Iketani, L. Liu, Y. Guo, L. Liu, Y. Huang, M. Wang, Y. Luo, J. Yu, M. T. Yin, M. E. Sobieszczyk, Y. Huang, H. H. Wang, Z. Sheng, D. D. Ho

This study characterizes the antigenic properties of SARS-CoV-2 Omicron sublineages BA.1+R346K and BA.2, showing they exhibit significant antibody evasion similar to BA.1.

bioRxiv · Feb 7, 2022Microbiology

Functional properties of the spike glycoprotein of the emerging SARS-CoV-2 variant B.1.1.529

Q. Wang, S. Anang, S. Iketani, Y. Guo, L. Liu, D. D. Ho, J. G. Sodroski

This study compares the functional properties of the B.1.1.529 SARS-CoV-2 spike glycoprotein with previous variants, finding reduced processing and lower stability but equivalent infection efficiency and increased ACE2 binding affinity.

bioRxiv · Dec 27, 2021Microbiology

Structural basis for antibody resistance to SARS-CoV-2 omicron variant

G. Cerutti, Y. Guo, L. Lihong, Z. Zhang, L. Liu, Y. Luo, Y. Huang, H. H. Wang, D. D. Ho, Z. Sheng, L. Shapiro

The paper reports a cryo-EM structure of the SARS-CoV-2 Omicron spike protein, revealing how mutations alter its conformation and enable antibody resistance.

bioRxiv · Dec 21, 2021 · PreprintImmunology

Striking Antibody Evasion Manifested by the Omicron Variant of SARS-CoV-2

L. Liu, S. Iketani, Y. Guo, J. F.-W. Chan, M. Wang, L. Liu, Y. Luo, H. Chu, Y. Huang, M. S. Nair, J. Yu, K. K.-H. Chik, T. T.-T. Yuen, C. Yoon, K. K.-W. To, , D. D. Ho

This study shows that the Omicron variant of SARS-CoV-2 is highly resistant to neutralization by convalescent serum and vaccines, and many monoclonal antibodies.

bioRxiv · Dec 14, 2021Microbiology

Isolation and comparative analysis of antibodies that broadly neutralize sarbecoviruses

L. Liu, S. Iketani, Y. Guo, R. Casner, E. Reddem, M. S. Nair, J. Yu, J. Chan, M. Wang, G. Cerutti, Z. Li, C. Castagna, L. Corredor, H. Chu, S. Yuan, , D. D. Ho

The paper identifies a human monoclonal antibody that neutralizes all tested sarbecoviruses and describes a new antibody class with potential for pandemic preparedness.

bioRxiv · Dec 11, 2021 · PreprintMicrobiology

A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses

P. Wang, R. G. Casner, M. S. Nair, J. Yu, Y. Guo, M. Wang, J. F. W. Chan, G. Cerutti, S. Iketani, L. Liu, Z. Sheng, Z. Chen, K.-Y. Yuen, P. D. Kwong, Y. Huang, , D. D. Ho

This paper identifies a monoclonal antibody, 2-36, that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses, with a conserved epitope in the RBD identified through cryo-EM.

bioRxiv · Oct 13, 2021Microbiology

SARS-CoV-2 hijacks neutralizing dimeric IgA for enhanced nasal infection and injury

B. Zhou, R. Zhou, J. F.-W. Chan, J. Zeng, Q. Zhang, S. Yuan, L. Liu, R. Robinot, S. Shan, J. Ge, H. Y.-H. Kwong, D. Zhou, H. Xu, C. C.-S. Chan, V. K.-M. Poon, , Z. Chen

This study shows that dimeric IgA antibodies can enhance SARS-CoV-2 nasal infection and injury in Syrian hamsters by engaging CD209 as an alternative receptor.

bioRxiv · Oct 5, 2021 · PreprintMicrobiology

Neutralizing antibody 5-7 defines a distinct site of vulnerability in SARS-CoV-2 spike N-terminal domain

G. Cerutti, Y. Guo, P. Wang, M. S. Nair, Y. Huang, J. Yu, L. Liu, P. S. Katsamba, F. Bahna, E. R. Reddem, P. D. Kwong, D. D. Ho, Z. Sheng, L. Shapiro

This paper reports the cryo-EM structure of antibody 5-7, which binds to a distinct site in the SARS-CoV-2 spike NTD, showing neutralization resistance to variants of concern.

bioRxiv · Jun 29, 2021Immunology